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TITLE OF CASE Do not include “a case report” 
Recurrent venous thromboembolism after discontinuation of rivaroxaban therapy in a 
patient with antiphospholipid syndrome 
SUMMARY Up to 150 words summarising the case presentation and outcome (this 
will be freely available online) 
A Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by 
thrombembolic events including thromboembolism (VTE) in association with the presence of 
antiphospholipid antibodies. The standard treatment of VTE historically consists of 
anticoagulation therapy with warfarin, a vitamin K antagonist. Recently, direct oral 
anticoagulants, including rivaroxaban have become available for the treatment of VTE. 
However, the choice of anticoagulant, and the duration of anticoagulation in patients with 
APS has not been determined yet due to lack of evidence. 
Here, we report a case of recurrent venous thrombosis after discontinuation of rivaroxaban 
therapy and avoiding sedentary life style in a patient with APS. We suggest that indefinite 
anticoagulation therapy might be needed even in low risk APS cases. 
BACKGROUND Why you think this case is important – why did you write it up? 
Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized 
by thromboembolic events or pregnancy morbidity in association with the presence 
of antiphospholipid antibodies. The standard treatment of venous thromboembolism 
(VTE) historically consists of anticoagulation therapy with warfarin, a vitamin K 
antagonist [1]. Recently, direct oral anticoagulants (DOACs), including rivaroxaban 
have become available for the treatment of VTE [2].  
However, the choice of anticoagulant, and the duration of anticoagulation in patients with 
APS has not been determined yet due to lack of evidence. Life-long anticoagulation for 
secondary prevention of VTE is recommended in high risk APS patients, but duration of 
anticoagulation therapy should be determined based on patient-specific risk-benefit ratio. 
Discontinuation of anticoagulation might be considered in low risk patients with provoked 
VTE.  
Here, we report a case of recurrent venous thrombosis after discontinuation of 
rivaroxaban therapy and avoiding sedentary life style in a patient with APS. We 
suggest that indefinite anticoagulation therapy might be needed even in low risk 
APS cases. 
CASE PRESENTATION Presenting features, medical/social/family history 
A 61-year-old man presented at our hospital with a swelling and pain in his left leg and a 
history of being sedentary for more than 8 hours in a day. He had a history of chronic 
gastritis, smoking since 40 years, and no family history of thrombosis. The enhanced 
computed tomography (CT) showed thrombosis extending from the left proximal femoral 
vein to the popliteal vein with bilateral PE (Figure 1A). The left iliac vein was not 
compressed by the right iliac vein, which excluded May-thurner syndrome or iliac 
vein compression syndrome. Blood examination demonstrated elevation of D-dimer to 3.2 
µg/mL, positive lupus anticoagulant, and negative anti-cardiolipin antibodies. Protein C, 
protein S, and antithrombin levels were within the normal range. APS was suspected as a 
cause of the VTE owing to the presence of thrombosis and positive lupus anticoagulant. 
He was administered a regular dose of 15 mg rivaroxaban and implantation of an inferior 
vena cava (IVC) filter, followed by a high dose of ribaroxaban (30 mg) for 21 days for acute 
VTE, with no heparin bridging.  
Venous echography revealed that the acute thrombus extending from the left femoral vein to 
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the popliteal vein was almost resolved in 14 days (Figure 2). The IVC filter was retrieved 
following the 14 days of dwell time. He was advised to avoid prolonged sitting and received 
15 mg of rivaroxaban. In 6 months, administration of rivaroxaban was discontinued because 
venous echography showed no recurrence of VTE and D-dimer was not elevated (0.3 µg/mL). 
However, 5 months later, he complained of the same symptoms in his left leg and presented 
to our hospital again. The enhanced CT showed thrombosis extending from the left proximal 
femoral vein to the popliteal vein, with bilateral PE, although the thrombi were smaller 
than the previous thrombi (Figure 1B). Blood examination showed elevated D-dimer (2.5 
µg/mL) and positive lupus anticoagulant. He was diagnosed with recurrent VTE complicated 
with APS. He was administered the same treatment with rivaroxaban after the temporary 
implantation of IVC filter and the thrombus was resolved.  
INVESTIGATIONS If relevant 
 
 
DIFFERENTIAL DIAGNOSIS If relevant 
 
 
TREATMENT If relevant  
 
 
 
OUTCOME AND FOLLOW-UP   
He is still visiting the hospital without symptoms. It was suggested that he continue to 
receive rivaroxaban therapy for life, as long as he did not experience major bleeding. 
 
DISCUSSION Include a very brief review of similar published cases  
In this case report, rivaroxaban was found to be effective for the treatment of VTE in a 
patient with APS, and that despite controlling a potential high risk trigger factor, 
recurrence of VTE was noted. 
APS is relatively rare, compared with other inherited thrombophilia conditions, such as 
protein S deficiency. It is known that antiphospholipid antibodies are present in 10% of 
patients with deep vein thrombosis [1]. Thus, we suggest testing of antiphospholipid 
antibodies in all patients with VTE to avoid misdiagnosis of APS.  
A small subset of patients with thrombophilic disorders (5–7%) was included in the 
EINSTEIN rivaroxaban trial; however, no specific information was recorded to identify the 
type of hypercoagulable disorder, and the antiphospholipid antibody status was also not 
systematically documented in the trial [2]. The guideline from the American College of 
Chest Physicians does not describe the treatment of VTE in patients with thrombophilia 
including APS, but describes thrombophilic disorders as a risk factor for recurrent VTE [3]. 
Thus, presence of APS could be suggested to have a role in the recurrence of VTE; however, 
the efficacy and safety of DOACs in preventing VTE in patients with APS has not been 
determined yet due to lack of evidence. 
A report on a case series showed that there was no recurrence of thrombosis during the 
mean follow-up period of data collection in 8 patients with APS after warfarin was switched 
to DOACs due to recurring thrombosis and bleeding in patients [4]. Another case series 
report showed that 4 out of 13 patients with APS had recurrent thrombosis during 
rivaroxaban treatment [5]. A retrospective study showed that 2 of 24 patients with APS had 
thrombosis recurrence during treatment with DOACs, the median duration of which was 31 
months [6]. The Rivaroxaban in Antiphospholipid Syndrome (RAPS) randomized controlled 
trial (RCT) showed that the percentage change in endogenous thrombin potential was 
higher in the rivaroxaban than in the warfarin group, indicating that rivaroxaban was 
inferior to warfarin in patients with APS. However, peak thrombin generation was lower 
with rivaroxaban; therefore, the overall thrombogram indicated no diﬀerence in thrombotic 
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risk in patients with APS [7]. This suggested that rivaroxaban is a potentially effective and 
convenient alternative to warfarin in thrombotic APS patients. A meta-analysis showed that 
16% of APS patients experienced a recurrent thrombosis while on DOACs with a mean 
duration of 12.5 months, indicating increased risk of thrombosis in APS patients treated 
with DOACs [8]. A systematic review of studies in patients with APS and recurrent 
thrombosis while on DOACs reported 19 cases of recurrent arterial or venous thrombosis out 
of 122 patients (15.6%) during a mean observation time of 12.6 months [9]. Thus, DOACs 
are not effective in all APS patients and should not be used routinely. Anticoagulant therapy 
with warfarin rather than a direct oral anticoagulant might be beneficial based on the lack 
of data regarding efficacy and safety of the DOACs in APS patients. Further clinical studies 
are needed to confirm the effectiveness of DOACs for VTE in patients with APS. The 
following RCTs are underway and results are awaited. Rivaroxaban in Thrombotic 
Antiphospholipid Syndrome (TRAPS), which is a randomized, controlled, open-label, 
noninferiority study, is investigating rivaroxaban 20 mg once daily compared to warfarin  in 
patients with APS with a history of thrombosis [10]. The ASTRO-APS RCT also compares 
the effectiveness and safety of apixaban with those of warfarin in secondary prevention of 
thromboembolism among patients with a history of APS and thrombosis 
(https://clinicaltrials.gov/). 
In patients with APS with a history of an unprovoked thrombotic event, lifelong 
anticoagulant therapy is based on the high likelihood of recurrence [11]. The benefit of 
prolonged anticoagulation is less certain in patients who are positive for antiphospholipid 
antibodies and in whom thrombosis was provoked [11]. However, discontinuation of 
anticoagulation in low-risk APS patients with a clearly provoked thrombosis, especially in 
the setting of low-titre antiphospholipid antibodies, can be considered after discussing the 
risks and benefits with the patient. We discontinued anticoagulation therapy 6 months after 
the first onset of VTE, because we thought he had low risk of recurrence of VTE due to the 
negative antiphospholipid antibody and lifestyle modification. However, he experienced 
recurrence of VTE, which was successfully treated. 
In conclusion, VTE could recur after discontinuation of anticoagulants in patients with APS 
complicated with provoked VTE; thus, life-long anticoagulation should be discussed with 
patients based on their risks and benefits. Additional evaluation of DOAC use in patients 
with APS is necessary to provide further evidence. 
 
LEARNING POINTS/TAKE HOME MESSAGES 3 to 5 bullet points – this is a required 
field 
・Prevalence of recurrent VTE is high in patients with APS. 
・Duration of anticoagulation therapy should be determined based on patient-specific risk-
benefit ratio in patients with APS. 
・ Life-long anticoagulation for secondary prevention of VTE should be discussed with APS 
patients based on their risk and benefit. 
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FIGURE/VIDEO CAPTIONS figures should NOT be embedded in this document 
 
Figure 1. Enhanced CT imaging shows thrombi in the pulmonary arteries and thrombus in 
the left femoral vein (arrow) 
Figure 2. Venous echographic imaging treatment showing thrombus in the left femoral vein 
before rivaroxaban (A blue arrow) and thrombus resolved after rivaroxaban treatment (B 
blue arrow). Red arrow indicates superficial femoral artery. 
 
PATIENT’S PERSPECTIVE Optional but strongly encouraged – this has to be written 
by the patient or next of kin 
 
N/A 
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